PCSK9 and atherosclerosis: Recent reports showed that changes in the expression of microRNAs are closely linked with the therapeutic actions of statins and effectively reduced atherosclerosis plaque formation/rupture through direct or indirect regulation of β-hydroxy, β-methylglutaryl-CoA (HMG-CoA) reductase, and cytochrome P450 3A and inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) to lower LDL uptake via suppressing LDL receptors [64].